ITPKC susceptibility in Kawasaki syndrome as a sensitizing factor for autoimmunity and coronary arterial wall relaxation induced by thimerosal's effects on calcium signaling via IP3

Autoimmunity Reviews

Volumn 11, Issue 12, 2012, Pages 903-908

  Yeter, Deniz ^a   Deth, Richard ^b  

^a Northeastern University ^*

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Autoimmunity; Inositol 1,4,5 triphosphate; Kawasaki syndrome; Mercury; Thimerosal; Vaccination

Indexed keywords

ALUMINUM; BACTERIUM LIPOPOLYSACCHARIDE; BCG VACCINE; CADMIUM; CALCIUM; CALCIUM ACTIVATED POTASSIUM CHANNEL; GLUTATHIONE; INOSITOL 1,4,5 TRIPHOSPHATE KINASE C; INOSITOL 1,4,5 TRISPHOSPHATE; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; LEAD; MANGANESE; MERCURY; PERTUSSIS VACCINE; PHOSPHOTRANSFERASE; THIOMERSAL; UNCLASSIFIED DRUG; ZINC;

ARTERY WALL; AUTOIMMUNITY; BLOOD VESSEL PERMEABILITY; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL TYPE; CORONARY ARTERY; GENOTYPE ENVIRONMENT INTERACTION; HLA SYSTEM; HUMAN; HYPERPOLARIZATION; IMMUNOCOMPETENT CELL; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; OXIDATIVE STRESS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ACRODYNIA; AUTOIMMUNITY; CALCIUM SIGNALING; CAPILLARY PERMEABILITY; CHILD; CORONARY VESSELS; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE; MUCOCUTANEOUS LYMPH NODE SYNDROME; OXIDATIVE STRESS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); POLYMORPHISM, SINGLE NUCLEOTIDE; THIMEROSAL;

EID: 84866554240     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.03.006     Document Type: Review

References (66)

1. Onouchi Y., Gunji T., Burns J.C., Shimizu C., Newburger J.W., Yashiro M., et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet Jan 2008, 40(1):35-42.
2. Kuo H.C., Yang K.D., Juo S.H., Liang C.D., Chen W.C., Wang Y.S., et al. ITPKC single nucleotide polymorphism associated with the Kawasaki disease in a Taiwanese population. PLoS One Apr 14 2011, 6(4):e17370.
3. Lin M.T., Wang J.K., Yeh J.I., Sun L.C., Chen P.L., Wu J.F., et al. Clinical implication of the C allele of the ITPKC gene SNP rs28493229 in Kawasaki disease: association with disease susceptibility and BCG scar reactivation. Pediatr Infect Dis J Feb 2011, 30(2):148-152.
4. Chi H., Huang F.Y., Chen M.R., Chiu N.C., Lee H.C., Lin S.P., et al. ITPKC gene SNP rs28493229 and Kawasaki disease in Taiwanese children. Hum Mol Genet Mar 15 2010, 19(6):1147-1151.
5. Schurmans S., Pouillon V., Maréchal Y. Regulation of B cell survival, development and function by inositol 1,4,5-trisphosphate 3-kinase B (ITPKB). Adv Enzyme Regul 2011, 51(1):66-73.
6. Onouchi Y. Identification of susceptibility genes for Kawasaki disease. Nihon Rinsho Meneki Gakkai Kaishi 2010, 33(2):73-80.
7. Goth S.R., Chu R.A., Gregg J.P., Cherednichenko G., Pessah I.N. Uncoupling of ATP-mediated calcium signaling and dysregulated interleukin-6 secretion in dendritic cells by nanomolar thimerosal. Environ Health Perspect Jul 2006, 114(7):1083-1091.
8. Joseph S.K., Nakao S.K., Sukumvanich S. Reactivity of free thiol groups in type-I inositol trisphosphate receptors. Biochem J Jan 15 2006, 393(Pt 2):575-582.
9. Bultynck G., Szlufcik K., Kasri N.N., Assefa Z., Callewaert G., Missiaen L., et al. Thimerosal stimulates Ca2+ flux through inositol 1,4,5-trisphosphate receptor type 1, but not type 3, via modulation of an isoform-specific Ca2+-dependent intramolecular interaction. Biochem J Jul 1 2004, 381(Pt 1):87-96.
10. Edwards D.H., Li Y., Griffith T.M. Hydrogen peroxide potentiates the EDHF phenomenon by promoting endothelial Ca2+ mobilization. Arterioscler Thromb Vasc Biol Oct 2008, 28(10):1774-1781.
11. Crack P., Cocks T. Thimerosal blocks stimulated but not basal release of endothelium-derived relaxing factor (EDRF) in dog isolated coronary artery. Br J Pharmacol Oct 1992, 107(2):566-572.
12. Rosenblum W.I., Nishimura H., Ellis E.F., Nelson G.H. The endothelium-dependent effects of thimerosal on mouse pial arterioles in vivo: evidence for control of microvascular events by EDRF as well as prostaglandins. J Cereb Blood Flow Metab Jul 1992, 12(4):703-706.
13. Bény J.L. Thimerosal hyperpolarizes arterial smooth muscles in an endothelium-dependent manner. Eur J Pharmacol Aug 28 1990, 185(2-3):235-238.
14. Förstermann U., Goppelt-Strübe M., Frölich J.C., Busse R. Thimerosal, an inhibitor of endothelial acyl-coenzyme A: lysolecithin acyltransferase, stimulates the production of a nonprostanoid endothelium-derived vascular relaxing factor. Adv Prostaglandin Thromboxane Leukot Res 1987, 17B:1108-1111.
15. Förstermann U., Burgwitz K., Frölich J.C. Thimerosal induces endothelium-dependent vascular smooth muscle relaxations by interacting with thiol groups. Relaxations are likely to be mediated by endothelium-derived relaxing factor (EDRF). Naunyn Schmiedebergs Arch Pharmacol Dec 1986, 334(4):501-507.
16. Griffith T.M. Endothelium-dependent smooth muscle hyperpolarization: do gap junctions provide a unifying hypothesis?. Br J Pharmacol Mar 2004, 141(6):881-903.
17. Kim J.J., Hong Y.M., Sohn S., Jang G.Y., Ha K.S., Yun S.W., et al. Korean Kawasaki Disease Genetics Consortium. A genome-wide association analysis reveals 1p31 and 2p13.3 as susceptibility loci for Kawasaki disease. Hum Genet May 2011, 129(5):487-495.
18. Kim J.J., Hong Y.M., Yun S.W., Han M.K., Lee K.Y., Song M.S., et al. Korean Kawasaki Disease Genetics Consortium. Assessment of risk factors for Korean children with Kawasaki disease. Pediatr Cardiol Apr 2012, 33(4):513-520.
19. Uchida N., Asayama K., Dobashi K., Hayashibe H., Kato K. Antioxidant enzymes and lipoperoxide in blood in patients with Kawasaki disease. Comparison with the changes in acute infections. Acta Paediatr Jpn Jun 1990, 32(3):242-248.
20. Sekine K., Mochizuki H., Inoue Y., Kobayashi T., Suganuma E., Matsuda S., et al. Regulation of oxidative stress in patients with Kawasaki disease. Inflammation Oct 20 2011, [Electronic publication ahead of print].
21. Ahn Y.J., Han M.Y. Association study of glutathione-S-transferase M1/T1 gene polymorphism in Korean children with Kawasaki disease. J Korean Pediatr Cardiol Soc Jun 2007, 11(2):131-137.
22. Aten J., Veninga A., De Heer E., Rozing J., Nieuwenhuis P., Hoedemaeker P.J., et al. Susceptibility to the induction of either autoimmunity or immunosuppression by mercuric chloride is related to the major histocompatibility complex class II haplotype. Eur J Immunol Mar 1991, 21(3):611-616.
23. Bagenstose L.M., Salgame P., Monestier M. Murine mercury-induced autoimmunity: a model of chemically related autoimmunity in humans. Immunol Res 1999, 20(1):67-78.
24. 2-treated mice. Clin Immunol Immunopathol Sep 1997, 84(3):328-337.
25. Oh J.H., Han J.W., Lee S.J., Lee K.Y., Suh B.K., Koh D.K., et al. Polymorphisms of human leukocyte antigen genes in Korean children with Kawasaki disease. Pediatr Cardiol Mar 2008, 29(2):402-408.
26. Lin Y.J., Wan L., Wu J.Y., Sheu J.J., Lin C.W., Lan Y.C., et al. HLA-E gene polymorphism associated with susceptibility to Kawasaki disease and formation of coronary artery aneurysms. Arthritis Rheum Feb 2009, 60(2):604-610.
27. Kim J.J., Hong S.J., Hong Y.M., Kim S., Kang M.J., Kim K.J., et al. Genetic variants in the HLA-G region are associated with Kawasaki disease. Hum Immunol Dec 2008, 69(12):867-871.
28. Hsieh Y.Y., Lin Y.J., Chang C.C., Chen D.Y., Hsu C.M., Wang Y.K., et al. Human lymphocyte antigen B-associated transcript 2, 3, and 5 polymorphisms and haplotypes are associated with susceptibility of Kawasaki disease and coronary artery aneurysm. J Clin Lab Anal 2010, 24(4):262-268.
29. Nelson E.A., Gottshall R.Y. Enhanced toxicity for mice of pertussis vaccines when preserved with merthiolate. Appl Microbiol May 1967, 15(3):590-593.
30. Abedi-Valugerdi M., Nilsson C., Zargari A., Gharibdoost F., DePierre J.W., Hassan M. Bacterial lipopolysaccharide both renders resistant mice susceptible to mercury-induced autoimmunity and exacerbates such autoimmunity in susceptible mice. Clin Exp Immunol Aug 2005, 141(2):238-247.
31. Minami T., Oda K., Gima N., Yamazaki H. Effects of lipopolysaccharide and chelator on mercury content in the cerebrum of thimerosal-administered mice. Environ Toxicol Pharmacol Nov 2007, 24(3):316-320.
32. Minami T., Miyata E., Sakamoto Y., Yamazaki H., Ichida S. Induction of metallothionein in mouse cerebellum and cerebrum with low-dose thimerosal injection. Cell Biol Toxicol Apr 2010, 26(2):143-152.
33. Inman R.D., Chiu B. Heavy metal exposure reverses genetic resistance to Chlamydia-induced arthritis. Arthritis Res Ther 2009, 11(1):R19.
34. Nakamura T., Yamamura J., Sato H., Kakinuma H., Takahashi H. Vasculitis induced by immunization with Bacillus Calmette-Guérin followed by atypical mycobacterium antigen: a new mouse model for Kawasaki disease. FEMS Immunol Med Microbiol Apr 2007, 49(3):391-397.
35. Schubert J., Riley E.J., Tyler S.A. Combined effects in toxicology-a rapid systematic testing procedure: cadmium, mercury, and lead. J Toxicol Environ Health Sep-Nov 1978, 4(5-6):763-776.
36. Duhr E.F., Pendergrass J.C., Slevin J.T., Haley B.E. HgEDTA complex inhibits GTP interactions with the E-site of brain beta-tubulin. Toxicol Appl Pharmacol Oct 1993, 122(2):273-280.
37. Wataha J.C., Nakajima H., Hanks C.T., Okabe T. Correlation of cytotoxicity with element release from mercury- and gallium-based dental alloys in vitro. Dent Mater Sep 1994, 10(5):298-303.
38. Papp A., Pecze L., Szabó A., Vezér T. Effects on the central and peripheral nervous activity in rats elicited by acute administration of lead, mercury and manganese, and their combinations. J Appl Toxicol Jul-Aug 2006, 26(4):374-380.
39. Haley B.E. Mercury toxicity: genetic susceptibility and synergistic effects. Med Veritas 2005, 535-542.
40. Salmon M.A., Wright T. Chronic copper poisoning presenting as pink disease. Arch Dis Child Feb 1971, 46(245):108-110.
41. Warkany J., Hubbard D.M. Adverse mercurial reactions in the form of acrodynia and related conditions. Am J Dis Child Mar 1951, 81(3):335-373.
42. Warkany J., Hubbard D.M. Acrodynia and mercury. J Pediatr Mar 1953, 42(3):365-386.
43. Abstracts of the 10th International Kawasaki Disease Symposium. February 7-10, 2012. Kyoto, Japan. Pediatr Int Feb 2012, 54 Suppl. 1:38-142.
44. Bauer E.L., Konzelmann F.W. A case of thrombo-angiitis with a clinical picture simulating acrodynia. Am J Dis Child 1930, 39(3):663-664.
45. Deth R.C. Congressional testimony before the U.S. House of Representatives. Subcommittee on human rights and wellness 2004.
46. Cameron A.W. L'Acrodynie 1931.
47. Hutton P.W. Case of acrodynia (pink disease) treated with dimercaptopropanol (BAL). East Afr Med J 1949, 26:263.
48. Daisley G.W., Clark H., McLendon P.A. Report of a case of acrodynia treated with BAL. Clin Proc Child Hosp Dist Columbia 1951, 7(7):178-181.
49. Miron D., Fink D., Hashkes P.J. Kawasaki disease in an infant following immunisation with hepatitis B vaccine. Clin Rheumatol 2003, 22(6):461-463.
50. Scardina G.A., Fucà G., Carini F., Valenza V., Spicola M., Procaccianti P., et al. Oral necrotizing microvasculitis in a patient affected by Kawasaki disease. Med Oral Patol Oral Cir Bucal Dec 1 2007, 12(8):E560-E564.
51. Bell D.M., Brink E.W., Nitzkin J.L., Hall C.B., Wulff H., Berkowitz I.D., et al. Kawasaki syndrome: description of two outbreaks in the United States. N Engl J Med Jun 25 1981, 304(26):1568-1575.
52. Treadwell T.A., Maddox R.A., Holman R.C., Belay E.D., Shahriari A., Anderson M.S., et al. Investigation of Kawasaki syndrome risk factors in Colorado. Pediatr Infect Dis J Oct 2002, 21(10):976-978.
53. Center K.J., Hansen J.R., Lewis E., Fireman B.H., Hilton B. Lack of association of Kawasaki disease after immunization in a cohort of infants followed for multiple autoimmune diagnoses in a large, phase-4 observational database safety study of 7-valent pneumococcal conjugate vaccine: lack of association between Kawasaki disease and seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J May 2009, 28(5):438-440.
54. Hua W., Izurieta H.S., Slade B., Belay E.D., Haber P., Tiernan R., et al. Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990-2007. Pediatr Infect Dis J Nov 2009, 28(11):943-947.
55. Onouchi Z., Ikuta K., Nagamatsu K., Tamiya H., Sakakibara Y., Ando M. Coronary artery aneurysms develop in weanling rabbits with serum sickness but not in mature rabbits. An experimental model for Kawasaki disease in humans. Angiology Aug 1995, 46(8):679-687.
56. Philip S., Lee W.C., Liu S.K., Wu M.H., Lue H.C. A swine model of horse serum-induced coronary vasculitis: an implication for Kawasaki disease. Pediatr Res Feb 2004, 55(2):211-219.
57. Harris F.E., Turner D.R., Oliveira D.B. Early vasculitis in the mercuric chloride induced Brown Norway rat model is neutrophil independent. Int J Exp Pathol Jun 1999, 80(3):133-142.
58. Nakamura S. The role of nitric oxide in mercury chloride-induced vasculitis in the Brown Norway rat. Nippon Jinzo Gakkai Shi Jul 1997, 39(5):447-454.
59. Mathieson P.W., Thiru S., Oliveira D.B. Mercuric chloride-treated Brown Norway rats develop widespread tissue injury including necrotizing vasculitis. Lab Invest Jul 1992, 67(1):121-129.
60. Bernaudin J.F., Druet E., Belair M.F., Pinchon M.C., Sapin C., Druet P. Extrarenal immune complex type deposits induced by mercuric chloride in the Brown Norway rat. Clin Exp Immunol Nov 1979, 38(2):265-273.
61. Pusey C.D., Bowman C., Morgan A., Weetman A.P., Hartley B., Lockwood C.M. Kinetics and pathogenicity of autoantibodies induced by mercuric chloride in the Brown Norway rat. Clin Exp Immunol Jul 1990, 81(1):76-82.
62. Qasim F.J., Thiru S., Gillespie K. Gold and d-penicillamine induce vasculitis and up-regulate mRNA for IL-4 in the Brown Norway rat: support for a role for Th2 cell activity. Clin Exp Immunol Jun 1997, 108(3):438-445.
63. Hornig M., Chian D., Lipkin W.I. Neurotoxic effects of postnatal thimerosal are mouse strain dependent. Mol Psychiatry Sep 2004, 9(9):833-845.
64. Epstein B. Pink disease and teething powders. S Afr Med J Sep 19 1953, 27(38):823-827.
65. Martindale W. The extra pharmacopoeia 1982, vol 2. Pharmaceutical Press, Pharmaceutical Society of Great Britain. London.
66. Mutter J. Is dental amalgam safe for humans? The opinion of the scientific committee of the European Commission. J Occup Med Toxicol Jan 13 2011, 6(2):1-17.